Syphilis Rapid Test Market Size Worth $ 399.89 Million By 2034 | CAGR: 8.39%

The global Syphilis Rapid Test market size is expected to reach USD 399.89 million by 2034, according to a new study by Polaris Market Research. The report, “Syphilis Rapid Test Market Size, Share, Trends, & Industry Analysis Report By Test Type (Dual HIV/Syphilis Rapid Test, Triple HIV/Hepatitis B/Syphilis Rapid Test, Syphilis-Only Rapid Test), By Sample Type, By End User, By Region – Market Forecast, 2026–2034” provides detailed analysis of market trends, growth factors, key segments, technology developments, product launches, regulatory activity, and regional outlook.

The syphilis rapid test market focuses on standalone syphilis tests, such as treponema pallidum antibody tests. It also emphasizes multiplex products that combine syphilis testing with HIV and other infectious disease diagnostics. The market is expanding as the rising burden of syphilis increases the need for faster diagnosis across antenatal care, STI screening, public health, and community testing programs. Treponemal rapid tests remain widely used for screening, while dual HIV/syphilis and newer multiplex testing formats are expanding the role of rapid diagnostics across maternal and public health programs.

Multiplex testing is creating lucrative opportunities for rapid diagnostic makers. In July 2025, the WHO prequalified the Determine Antenatal Care Panel, the first packaged set of rapid diagnostic tests for HIV, hepatitis B, and syphilis, which created a new model for testing in antenatal care. This development is increasing attention on integrated testing workflows that can simplify screening and improve access in resource limited settings.

New product development helps extend the competitive arena. In July 2025, the FDA granted a Breakthrough Device Designation to Chembio’s DPP Syphilis TnT Assay that aims at making POC testing of active syphilis possible through treponemal and non-treponemal testing. Abbott also received WHO prequalification for Determine Syphilis Advanced in 2026, adding a newer syphilis rapid test to its prequalified diagnostic portfolio.

Questions? Request a sample or make an inquiry before buying this report by clicking the link below: Syphilis Rapid Test Market Report

Syphilis Rapid Test Market Report Highlights

• Dual HIV/syphilis testing is the only format with two products holding both FDA clearance and CLIA waiver in the US, a regulatory bar most competitors still haven't cleared.
• Fingerstick collection needs no refrigeration, no venipuncture equipment, and no trained phlebotomist, which is exactly why outreach programs like Philadelphia FIGHT's pharmacy partnership chose it.
• Every dollar spent on antenatal screening now does triple duty: WHO's prequalified panel checks HIV, hepatitis B, and syphilis status in one visit, one sample, one result window.
• North America's testing infrastructure has a 20-year head start on decentralized screening, a lead that's widening as HHS puts fresh federal money behind point-of-care expansion.
• Asia Pacific's growth isn't just demand-driven, the region doubles as a manufacturing base, which shortens the gap between a product launching and it reaching the clinics that need it.
• Major players include Abbott Diagnostics, SD Biosensor, Chembio Diagnostic Systems, Trinity Biotech, and bioLytical Laboratories, alongside recent entrants Shuwen Biotech and NOWDiagnostics.

Polaris Market Research has segmented the Syphilis Rapid Test Market report based on test type, sample type, end user, and region:

By Test Type Outlook (Revenue, USD Million, 2021–2034)

• Dual HIV/Syphilis Rapid Test
• Triple HIV/Hepatitis B/Syphilis Rapid Test
• Syphilis-Only Rapid Test

By Sample Type Outlook (Revenue, USD Million, 2021–2034)

• Fingerstick Whole Blood
• Serum / Plasma
• Other Sample Types

By End User Outlook (Revenue, USD Million, 2021–2034)

• Antenatal Care / Public Health Programs
• Hospitals & Clinics
• Community & Outreach Testing Programs
• Laboratories
• Other End Users

By Region Outlook (Revenue – USD Million, 2021–2034)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Australia
  • Malaysia
  • Rest of Asia Pacific
• Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa